Parnax Lab Q4 FY26 Results: Revenue Rs 252.33 Crore, Net Profit Rs 11.78 Crore and Key Highlights

Parnax Lab Q4 FY26 results were declared on May 28, 2026. The company reported net profit of Rs 11.78 crore for the quarter ended March 31, 2026. Revenue from operations was Rs 252.33 crore. Parnax Lab is a Pharmaceutical Formulations company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Parnax Lab Q4 FY26 Financial Highlights

Metric	Q4 FY26	Q4 FY25	YoY Change
Revenue from Operations (Rs Cr)	252.33	Prior Year	See BSE/NSE filing
Net Profit (PAT) (Rs Cr)	11.78	Prior Year	See BSE/NSE filing
Reporting Basis	Standalone / Consolidated (see BSE/NSE filing)

Data sourced from company filings and public disclosures. Always verify from BSE/NSE audited filings before investment decisions.

Parnax Lab Q4 FY26 Performance Analysis

The Parnax Lab Q4 FY26 results reflect performance in the January to March 2026 quarter. Revenue was Rs 252.33 crore as per the audited filing. Net profit of Rs 11.78 crore reflects the company operational performance. Parnax Lab operates in the Pharmaceutical Formulations sector.

India macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth above 6.5%, government capex of Rs 11.21 lakh crore for FY27, and the RBI accommodative policy stance. The Pharmaceutical Formulations sector benefited from these structural tailwinds during the January to March 2026 quarter.

Key Business Factors in Q4 FY26

Revenue and Volume Performance

Revenue from operations was Rs 252.33 crore in Q4 FY26 for Parnax Lab. The Pharmaceutical Formulations sector benefited from India domestic demand recovery and infrastructure push in FY26.

Profitability and Margin Trajectory

Q4 FY26 net profit of Rs 11.78 crore demonstrates the company performance.

Sector and Macro Backdrop

India macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI accommodative policy stance. The Pharmaceutical Formulations sector benefited from these structural tailwinds during the quarter ended March 31, 2026.

FY27 Outlook

Following the Parnax Lab Q4 FY26 results, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and business strategy. India GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Parnax Lab in FY27.

Parnax Lab Stock Performance

Download the Univest iOS App or Univest Android App to track live price and daily stock recommendations.

Shares of Parnax Lab are listed on NSE and BSE. Following the Q4 FY26 results on May 28, 2026, investors should monitor post-results price action and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.

Key Risks

Revenue and Demand Risk

Any deceleration in India GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Parnax Lab products and services in the Pharmaceutical Formulations sector in FY27.

Margin and Cost Volatility

Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks. Any cost escalation without corresponding pricing power could compress profitability.

Conclusion

Parnax Lab Q4 FY26 results declared on May 28, 2026 showed net profit of Rs 11.78 crore. Investors should monitor management guidance and sector trends before making investment decisions.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE/NSE audited filings.

Frequently Asked Questions on Parnax Lab Q4 FY26 Results

What is Parnax Lab Q4 FY26 net profit?

Ans. Parnax Lab Q4 FY26 net profit was Rs 11.78 crore. Results declared May 28, 2026.

What is Parnax Lab Q4 FY26 revenue?

Ans. Parnax Lab Q4 FY26 revenue was Rs 252.33 crore.

When were Parnax Lab Q4 FY26 results declared?

Ans. Parnax Lab Q4 FY26 results were declared on May 28, 2026 at the board meeting approving audited financial statements for the quarter and year ended March 31, 2026.

What is the FY27 outlook for Parnax Lab?

Ans. Following Parnax Lab Q4 FY26 results, management guidance on revenue growth, margin improvement, and sector dynamics shapes FY27 expectations. Consult a SEBI-registered advisor before investing.

Is Parnax Lab a good stock to buy after Q4 FY26 results?

Ans. Investment decisions require assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This content is educational only. Consult a SEBI-registered financial advisor.

What sector does Parnax Lab operate in?

Ans. Parnax Lab operates in the Pharmaceutical Formulations sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 28, 2026.